Syros Pharmaceuticals (SYRS) Competitors $0.0016 +0.00 (+33.33%) As of 08/1/2025 03:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYRS vs. NMTR, PTPI, TRVN, PBLA, BPTSY, HEPA, VIRX, NCNA, MYMD, and CAPSShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), Trevena (TRVN), Panbela Therapeutics (PBLA), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Viracta Therapeutics (VIRX), NuCana (NCNA), MyMD Pharmaceuticals (MYMD), and Capstone Therapeutics (CAPS). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Its Competitors 9 Meters Biopharma Petros Pharmaceuticals Trevena Panbela Therapeutics Biophytis Hepion Pharmaceuticals Viracta Therapeutics NuCana MyMD Pharmaceuticals Capstone Therapeutics Syros Pharmaceuticals (NASDAQ:SYRS) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Do institutionals and insiders believe in SYRS or NMTR? 91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor SYRS or NMTR? In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score. Company Overall Sentiment Syros Pharmaceuticals Neutral 9 Meters Biopharma Neutral Is SYRS or NMTR more profitable? 9 Meters Biopharma's return on equity of -584.97% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% 9 Meters Biopharma N/A -584.97%-159.45% Which has higher valuation & earnings, SYRS or NMTR? 9 Meters Biopharma has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K0.11-$164.57M-$3.030.009 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Do analysts prefer SYRS or NMTR? Syros Pharmaceuticals presently has a consensus price target of $3.33, indicating a potential upside of 208,233.33%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Syros Pharmaceuticals is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.209 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, SYRS or NMTR? Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. SummarySyros Pharmaceuticals beats 9 Meters Biopharma on 9 of the 12 factors compared between the two stocks. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43K$786.70M$5.47B$9.53BDividend YieldN/A4.84%4.73%4.09%P/E Ratio0.001.3728.8923.83Price / Sales0.1125.68371.4466.13Price / CashN/A19.5635.4557.96Price / Book0.006.688.265.54Net Income-$164.57M-$3.67M$3.25B$259.28M7 Day PerformanceN/A-5.23%-3.73%-4.66%1 Month PerformanceN/A-0.79%4.28%4.40%1 Year PerformanceN/A15.44%25.85%17.92% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.0223 of 5 stars$0.00+33.3%$3.33+208,233.3%-100.0%$43K$386K0.00120NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220PTPIPetros PharmaceuticalsN/A$0.03-2.9%N/A-99.7%$938K$5.11M-0.0120Gap DownTRVNTrevena1.5352 of 5 stars$0.91flat$5.00+449.5%-82.5%$873K$443K-0.0240Upcoming EarningsPBLAPanbela Therapeutics0.1643 of 5 stars$0.16flatN/A-55.3%$767KN/A0.006Short Interest ↑BPTSYBiophytisN/A$1.81flatN/AN/A$634KN/A0.0030HEPAHepion Pharmaceuticals0.4938 of 5 stars$0.05-12.2%N/A-99.9%$612KN/A-0.0120Gap UpVIRXViracta Therapeutics1.7153 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120Short Interest ↑NCNANuCana2.6728 of 5 stars$0.06-7.7%$25.00+45,354.5%-98.9%$360KN/A-0.0130News CoverageShort Interest ↑MYMDMyMD PharmaceuticalsN/A$0.12-11.5%N/A-94.6%$277KN/A0.006Gap DownHigh Trading VolumeCAPSCapstone TherapeuticsN/A$1.56-2.2%N/AN/A$250K$44.88M0.0038Gap Down Related Companies and Tools Related Companies NMTR Alternatives PTPI Alternatives TRVN Alternatives PBLA Alternatives BPTSY Alternatives HEPA Alternatives VIRX Alternatives NCNA Alternatives MYMD Alternatives CAPS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
